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Erdheim–Chester disease (ECD) is a rare, non-Langerhans cell histiocytic disorder of
unknown cause characterized by heterogeneous systemic manifestations. The histiocytic
inﬁltration can affect bones, orbits, heart, kidneys, lungs, mediastinum, liver, spleen and
central nervous system. Corticosteroids are the ﬁrst-line treatment. The 3-year survival
rate for patients with ECD is approximately 50%. We report the case of a 31 year old male
ECD patient that have pulmonary ﬁbrosis, bone involvement and diabetes insipidus. He was
treated with systemic and inhaled corticosteroids and has remained stable for 53 months
after this rare type of treatment.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Figure 1
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Erdheim–Chester disease (ECD) is a rare, non-Langerhans
cell histiocytic disorder of unknown cause characterized by
heterogeneous systemic manifestations.1,2 Typically it af-
fects adults of both sexes with symmetric osteosclerosis of
the long bones sparing the epiphyses.3 ECD associated
Symptoms are variable.(Table 1).1,2 Extraskeletal lesions
are described in more than 50% of patients at the diagnosis 4
and 35% of patients with ECD develop pulmonary manifesta-
tions characterised by interstitial accumulations of histio-
cytic cells and ﬁbrosis in a predominantly perilymphangitic
and subpleural pattern. Mean survival is less than 3 years
and pulmonary ﬁbrosis is one of the most frequently
reported causes of death.1 We presented the case of a
patient with ECD that includes pulmonary ﬁbrosis, bone
involvement and diabetes insipidus who was treated with
only systemic and inhaled corticosteroids.Case
A 31 year old male soldier presented with right femur
fracture after falling down in March 2005. He also
complained of dyspnea, cough and wheezing. Bilateral
rhonchii were noted on chest examination. The soldier had
approximately a 20 pack-years smoking history. Previous
medical history included the identiﬁcation of bilateral
nodular and reticular lung densities detected during routine
chest radiograph in his workplace in 2003. Evaluation of
those densities included video-assisted thoracoscopic sur-
gery with lung biopsy, completed at another center. The
pathological diagnosis was non-speciﬁc pneumonitis and
focal interstitial ﬁbrotic proliferation with a clinical
diagnosis of interstitial lung disease treated with 12 months
of systemic corticosteroid therapy. At the time of the
diagnosis diffusing capacity of the lung for carbon monoxide
(DLCO) was 55%. Also spontaneous pneumothorax was
formed in left lung about one week ago before admission
and it was treated with chest tube.
On this admission, pelvic radiograph showed multiple,
well-deﬁned lytic lesions in the pelvis and femur with a
fracture through a large osteolytic lesion (Figure 1). Repair
of the fractured hip required a right hip prothesis. Pre-
operative chest radiograph showed a ﬁne reticulonodularTable 1 Signs and symptoms of Erdheim–Chester
disease1,2.
Common
Bone pain (knee, ankle)
Fever, weight loss, weakness, fatigue
Xanthomata or xanthelasma (eye)
Less common
Exophthalmos
Polyuria, polydipsia
Abdominal pain
Pruritic rash
Gait disturbance, seizure, impaired vision
Dyspnea, cough, cyanosis
Figure 2pattern throughout both lungs with relative sparing of the
costophrenic angles (Figure 2). Using thorax high-resolution
computed tomography (HRCT) examination, thin-walled
cystic spaces and a few irregular small nodules (arrows)
were seen (Figure 3a,b). Pulmonary function test showed an
FEV1 of 241 L (57% predicted), FVC: 433 L (85% predicted)
and FEV1/FVC: 56%.(Table 2) Arterial blood gas results were:
pH: 7,43, PaCO2:37mmHg, PaO2: 92mmHg, HCO3: 27mEq/L,
SatO2: 97% on room air.
Pathological examination of the resected bone materials
showed degenerative changes with compact histiocyte
inﬁltration in soft tissues. Adipose tissue was seen in the
bone marrow with patchy histiocytic inﬁltration also seen in
osteoid tissue. Figure 4a–c show histiocyts as stained with
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for CD1a and S-100 protein.
Laboratory results included: Na: 138mmol/L, K:
4.3mmol/L, Cl: 98mmol/L, Hb: 15.6 gr/dL, WBC: 8100/uL,
platelets: 423.000/uL, serum osmolality: 294mOsm/kg and
urine osmolality: 531mOsm/kg. PTH: 592 pg/ml (k), Calsi-
tonin: 19.0 pg/ml (m), fT3: 2.72 pg/ml (normal), fT4:
1.26 ng/dl (normal) and TSH: 1.68 IU/ml (normal). Serum
alkaline phosphatase and immunoglobulin levels were
normal. To further evaluate his insipidus, hypophysis MRI
imaging was performed and absence of the normal high
signal intensity of the neurohypophysis. (Figure 5).Table 2 Pulmonary function tests during follow up.
Date FEV1 (L-% pred) FVC (L-% pred) FEV1/F
10.10.2003
21.03.2006 2.41–57 4.33–85 56
22.06.2006 2.05–48 4.05–79 50
17.08.2006 2.52–59 4.42–86 57
19.12.2006 2.18–51 4.08–80 54
03.04.2007 2.11–50 3.90–77 54
Figure 3All of these ﬁndings consist of ECD and treatment was
begun with inhaled combination of 640mcg/day of budeso-
nide and 18mcg/day of formoterol accompanied by smoking
cessation recommendations. And also nasal vasopressin
treatment began for diabetes insipidus. In October 2007 he
was admitted in the emergency department for the sudden
onset of dypsnea and the examination showed a right
pneumothorax. Thoracostomy was performed to place a
chest tube (Figure 5). He continued to smoke.Discussion
In 1930, Chester described two patients with a distinctive
lipoidosis that was different from other histiocytic disorders.
The disease was characterized by the proliferation of
lipid containing foamy histiocyts in the skeleton, especially
in the long bones, without visceral involvement.4,5 The
histiocytic inﬁltration has been reported at many other
sites, including the retroperitoneum, orbits, heart, kidney,
lung, mediastinum, pelvis, liver, spleen, central nervous
system and the pericardium.4,6 Central nervous system
involvement generally manifests itself as central diabetes
insipidus or as cerebellar or brainstem symptoms.6 Bone pain
is the most common presenting symptom of ECD, occurring
in approximately 50% of patients.1,6,7 Pulmonary ECD
typically present with dyspnea and sometimes a dry
cough.8 Our case was presented ﬁrstly with dyspnea and
dry cough, than with a pathologcal fracture of femur
because of lytic lesion. Diabetes insipidus was also diag-
nosed in our patient.
More than 240 ECD cases have been reported in Ref. [9].
The mean age of patients with ECD is 53 years (714 years)
and there is a slight male predominance.6,7 Our patient was
31 at the time of diagnosis and in the literature few cases
are diagnosed in people under 40 years of age.
Radiographically, ECD is characterized by a diffuse
increase in bone density with a coarsened trabecular
pattern, as well as cortical sclerosis and thickening involving
the long tubular bones. Symmetrical long-bone osteosclero-
sis is the radiologic sign speciﬁc for ECD. The most
frequently affected bones are the femur, tibia and ﬁbula,
and less commonly the ulna, radius and humerus. Lytic
lesions are unusual (5–8%) but it was there in our case.6,7
Histopathologically, tissues contain non-Langerhans
cell histiocytic inﬁltrates and dense ﬁbrotic tissue distinc-
tively localized to visceral pleura, interlobular septa, andVC(%) DLCO (ml CO/min/
mmHg-% pred)
DLCO/VA (LCO per
unit of alveolar
volume-% pred)
19.3–55
16.2–46 2.53–52
17.1–49 2.19–45
19.3–55 2.08–42
13.6–39 1.87–38
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Figure 5
Figure 4
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electron microscopy are important in deﬁning the histiocyte
subtype. Langerhans cell histiocytic diseases are character-
ized by the accumulation of CD1a-expressing cells that
contain CD68, S-100 protein, Birbeck granules, and a
grooved nucleus whereas non-Langerhans cell histiocytoses
(e.g., ECD) typically have inﬁltrates of lipid-laden cells that
lack Birbeck granules and stain positively for CD68, variably
for S-100 protein, and negatively for CD1a.1,9 In our case thehistiocyts were positive for CD68 but negative for CD1a and
S-100 protein.
Numerous treatments have been attempted for this
disease. Corticosteroids are the traditional ﬁrst-line treat-
ment and are used to control symptoms, but generally they
are either ineffective or only transiently effective.3 Bispho-
sphonates, chemotherapy, cladribine, radiation, methotrex-
ate, cyclosporine and azathioprine are the other treatment
options but these treatments are often ineffective.7,8,10
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improvement of lesions and symptoms are detected in
some cases.3,5,9 Our case had been treated previously
for a diagnosis of diffuse interstitial ﬁbrosis using
90mg/day of deﬂazacort for a period of 12 months with
improvement. We therefore chose to use only inhaled
budesonide and formoterol and his symptoms appear to be
well controlled.
ECD have poor prognosis and most of the patients die
within 3 years.7,9 Our patient was initially incorrectly
diagnosed as interstitial lung ﬁbrosis in May 2003 and he is
alive for about 4.5 years (53 months) later using oral and
inhaled corticosteroid treatment with less dyspnea and
imporoved general well being.
In conclusion, we present a case of ECD initially diagnosed
as interstitial lung disease occurring at a young age. The
patient has typical ﬁndings including lung, bone and
hypophysis involvement with slow progression of the disease
that appears to be stabilized by corticosteroids.Acknowledgment
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